Oramed Pharmaceuticals Inc. key statistics and ratios

In fiscal 2025, Oramed Pharmaceuticals Inc. had return on equity of 35.2%, an operating margin of -754.4%, debt equal to 0.3% of equity and a current ratio of 6.98. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Oramed Pharmaceuticals Inc.: financial ratios, annual
Fiscal year	2016Aug 2016	2017Aug 2017	2018Aug 2018	2019Aug 2019	2020Aug 2020	2021Aug 2021	2022Dec 2022	2023Dec 2023	2025Dec 2025
Gross margin	23.6%	92.4%	—	96.7%	—	—	—	—	0.7%
Operating margin	<−999%	−438.6%	−552.3%	−541.3%	−433.8%	−896.2%	<−999%	<−999%	−754.4%
Net margin	<−999%	−426.7%	−519.7%	−531.1%	−424.8%	−850.5%	<−999%	379.7%	>999%
Free-cash-flow margin	724.8%	−237.7%	−598.7%	−479.3%	−462.1%	−797.5%	<−999%	−787.2%	−457.7%
Return on equity	−41.9%	−46.1%	−50.6%	−56.8%	−44.0%	—	−24.1%	3.2%	35.2%
Return on assets	−25.6%	−25.7%	−29.6%	−35.0%	−29.0%	−26.6%	−25.2%	2.7%	28.4%
Asset turnover	0.01	0.06	0.06	0.07	0.07	0.03	0.02	0.01	0.01
Current ratio	8.62	3.93	6.82	6.28	8.93	14.27	27.34	3.06	6.98
Debt to equity	0.0%	0.0%	44.5%	63.7%	—	—	0.0%	31.1%	0.3%
Interest cover (operating income ÷ interest)	—	—	—	—	—	—	—	n/m	—
Effective tax rate	—	—	—	—	—	—	—	—	15.0%
R&D as % of revenue	>999%	418.6%	489.1%	500.3%	377.7%	776.5%	>999%	669.5%	319.1%
Capital spending as % of revenue	1.4%	0.3%	0.2%	0.6%	3.0%	13.9%	18.4%	19.0%	0.5%
Free cash flow ÷ net income	—	—	—	—	—	—	—	−207.3%	−14.3%

US$ thousands unless shown otherwise. Fiscal quarters.

Oramed Pharmaceuticals Inc.: financial ratios, quarterly
Quarter	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025
Gross margin	—	—	—	—	0.7%	—	—	—
Operating margin	−782.0%	−562.5%	—	—	−225.0%	—	—	—
Net margin	−509.8%	−177.2%	—	—	−382.1%	—	—	—
Free-cash-flow margin	−863.1%	−393.8%	—	—	−176.1%	—	—	—
Current ratio	31.21	141.49	2.25	3.06	23.94	26.81	22.25	6.98
Debt to equity	—	—	100.5%	31.1%	—	—	—	—
R&D as % of revenue	664.7%	270.2%	—	—	110.3%	—	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 1 checks passed · June 30, 2026

What it owns · $370m

Short-term assets $53mLonger-term assets $316m

What it owes, and who funded it · $328m

Short-term liabilities $11mShareholders' equity $317m

Short-term assets cover short-term liabilities $53m of assets due within a year against $11m of liabilities due within a year.
Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Oramed Pharmaceuticals Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

8 /100

Weak moat

How hard Oramed Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -14.9% of total assets over 9 years.
Durability 10 / 20

Operating margin has been a median -705.1%; its worst year was -1278.4%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 5 years, at a median -562.5% of revenue.
Discipline 0 / 20

The diluted share count rose 70.7% over five years; stock-based pay has been a median 43.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: KRSA vs ORMP MCRB vs ORMP CLGN vs ORMP

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Oramed Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Oramed Pharmaceuticals Inc.